Oncology Business Management | Specialty

The OncLive Oncology Business Management condition center page is a comprehensive resource for news and expert insights on business-focused updates and topics in oncology practices, including diversity efforts, telehealth, gaps in care, payment models, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates and best practices with oncology business management.

FDA Approves CPX-351 for Two Types of AML

August 3rd 2017

The FDA has approved CPX-351 for adult patients with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.

Maintenance Olaparib Data Published as FDA Weighs Approval

August 1st 2017

The FDA granted a priority review in March to a new drug application for maintenance olaparib, and is scheduled to make its final decision on the PARP inhibitor before the end of the year.

Frontline Durvalumab Plus Tremelimumab Falls Short in Phase III NSCLC Trial

July 27th 2017

Frontline durvalumab (Imfinzi) did not improve progression-free survival in patients with stage IV metastatic non–small cell lung cancer compared with standard platinum-based chemotherapy.

FDA Accepts sBLAs for 4-week Nivolumab Dosing Schedule

July 26th 2017

The FDA has accepted supplemental Biologics License Applications seeking to add a second dosing schedule for nivolumab (Opdivo) across all of the PD-1 inhibitor’s monotherapy indications.

ASCO Calls for Drug Pricing Reforms

July 19th 2017

As rumors circulate in Washington, DC, ASCO has called for efforts to reach a consensus on drug value to ensure affordability and access for patients and spur manufacturers to work harder on bringing innovative medicines to market.

ODAC Votes to Recommend Approval for Trastuzumab Biosimilar MYL-1401O

July 14th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 to recommend approval to MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals.

Immunotherapy for Operable NSCLC

July 13th 2017

Novel Immunotherapy Combinations for NSCLC

July 13th 2017

Emerging Immunotherapies and Combinations for NSCLC

July 13th 2017

Unmet Needs: Sequencing After Immunotherapy in NSCLC

July 13th 2017

Questions Surrounding Therapeutic Sequencing for NSCLC

July 13th 2017

Immunotherapy for Relapsed/Refractory NSCLC

July 13th 2017

Early Experience; Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

Upfront Immunotherapy + Chemotherapy for NSCLC

July 13th 2017

Upfront Immunotherapy for NSCLC

July 13th 2017

The Ever-Evolving Treatment Paradigm for NSCLC

July 13th 2017

ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215

July 13th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.

HER2 Status in Colorectal Cancer

July 13th 2017

Evidence in BRAF-Mutant CRC Tumors

July 13th 2017

CRC: Emerging Immunotherapy Strategies in MSS Tumors

July 13th 2017